Free Trial
NASDAQ:GNLX

Genelux 5/8/2025 Earnings Report

Genelux logo
$2.58 +0.09 (+3.61%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.60 +0.02 (+0.58%)
As of 05/23/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genelux EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.24
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Genelux Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genelux Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genelux Earnings Headlines

Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)
Genelux reports FY24 EPS (95c), consensus (88c)
See More Genelux Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email.

About Genelux

Genelux (NASDAQ:GNLX), a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

View Genelux Profile

More Earnings Resources from MarketBeat